GLP-1 agonists for weight loss: pharmacology and clinical implications.
The DOI matches its Crossref record; 29 of the 32 references it cites were found in a registry or an index.
Abstract
This review investigates the various pharmacologic treatments for overweight and obesity in adults, especially glucagon-like peptide 1 (GLP-1) agonists. In light of the globally expanding obesity pandemic and the limited selection of treatments, physicians must be equipped with knowledge regarding proven medications and their nuanced differences to best support patients on their path to a healthier lifestyle. In this review, we explore the current medical therapies for obesity, including all major categories, individual mechanisms of action, pharmacokinetics and pharmacodynamics, adverse effects, risks, and absolute contraindications. Additionally, we review the evidence of four recent clinical trials, two systematic reviews, and two meta-analyses describing the efficacy of GLP-1 agonists in decreasing weight, lowering HbA1c, and improving obesity comorbidities. We also discuss total cost and cost-effectiveness compared to other categories, long-term adherence, barriers to use, and reasons for discontinuation of this drug category. Our goal is that this review can serve as a framework to aid providers in building their knowledge and selecting the most advantageous weight loss medication for each patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Systematic reviews and meta-analyses of GLP-1 receptor agonists reported that subcutaneous semaglutide reduced weight and improved weight-related comorbidities significantly more than liraglutide and was associated with lower rates of gastrointestinal adverse events.101,102”
From Obesity Management in Adults: A Review (2023) · cites this paper as [101]
In the citing paper
“A number of reviews on similar topics have also been previously published [124-128], focusing on efficacy [125] or case reports [126], being narrative reviews [127,128], or including a much smaller sample of studies [124].”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [127]
Citations
Cites
1 retracted
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01640-8 · Cited by 279
RetractedOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“A recent 2021 meta-analysis of GLP-1 receptor agonists of randomized trials looked at eight trials comprising 60,080 patients and found that GLP-1 receptor agonists, regardless of structural homology, reduced major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsened k…”
BackgroundRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 2×
“Patients who received placebo treatment instead of treatment with semaglutide in clinical trials also experienced nausea and vomiting as well as other associated gastrointestinal side effects; however, their complaints were less frequent and severe [25].”
BackgroundFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
The menace of obesity to depression and anxiety prevalence
Fulton, S., Décarie-Spain, L., Fioramonti, X., Guiard, B., & Nakajima, S. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.10.005 · Cited by 441 · cited 1×
“Regarding the mental consequences of obesity, poor diet and lack of exercise, chronic inflammation, and insulin and leptin resistance have been identified as key risk factors for developing depression and anxiety [6].”
BackgroundHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356
Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01710-0 · Cited by 297
Research works printed but not linked: 3
- Sombra LRS, Anastasopoulou C. Pharmacologic therapy for obesity. StatPearls Internet. Treasure Island: StatPearls; 2021. https://www.ncbi.nlm.nih.gov/books/NBK562269/. Accessed 9 Jun 2022.
- Tchang BG, Aras M, Kumar RB, et al. Pharmacologic treatment of overweight and obesity in adults. Endotext. South Dartmouth: MDtext.com; 2021.
- Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls Internet. Treasure Island: StatPearls; 2022. https://www.ncbi.nlm.nih.gov/books/NBK551568/. Accessed 9 Jun 2022.
Cited by
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.
Watanabe, J. H., Kwon, J., Nan, B., & Reikes, A. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.10.002 · Cited by 216
Childhood Obesity, Diabetes, and Cardiovascular Disease Risk
Salama, M., Balagopal, B., Fennoy, I., & Kumar, S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad361 · Cited by 112
Arillotta, D., Floresta, G., Papanti Pelletier, G. D., Guirguis, A., Corkery, J. M., Martinotti, G., & Schifano, F. (2024) · Brain Sciences · doi:10.3390/brainsci14060617 · Cited by 64
Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications
Burke, O. M., Sa, B., Cespedes, D. A., & Tosti, A. (2025) · Skin Appendage Disorders · doi:10.1159/000544023 · Cited by 50
Metadata
- Authors
- Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D.
- Affiliations
- Louisiana State University (US)
- Louisiana State University Health Sciences Center New Orleans (US)
- Corresponding author
- Cornett, Elyse M.
- ORCID
- Venue
- Advances in Therapy
- Published
- 2022-12-24
- Volume
- 40
- Issue
- 3
- Pages
- 723-742
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W4312140562
- Cited by
- 86
- References
- 32
- Citations by year
- 2026: 30 · 2025: 30 · 2024: 18 · 2023: 8
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Advances in Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- GLP-1 receptor agonists, obesity treatment, weight loss, pharmacokinetics, pharmacodynamics, adverse effects, contraindications, HbA1c reduction, obesity-related comorbidities, cost-effectiveness, medication adherence, drug discontinuation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 agonists for weight loss: pharmacology and clinical implications. https://app.cochat.ai/papers/10.1007/s12325-022-02394-w
- The paper
- Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023). GLP-1 agonists for weight loss: pharmacology and clinical implications. Advances in Therapy. https://doi.org/10.1007/s12325-022-02394-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.